SecBot SecBot
8-K ·Filed Feb 25, 2026

ALKS

Alkermes plc.
MIXED
Impact 6/10
Horizonmonths Processed8mo ago SEC0001193125-26-068512
8-K Item 2.02: Earnings release
Actionable Insight ◆ Mixed

Monitor the integration of Avadel and the ramp-up of LUMRYZ sales, as the company transitions from profitability to a projected net loss in 2026 due to acquisition accounting. The success of alixorexton's phase 3 trials will be critical for long-term value creation.

DirectionMixed
Confidencehigh
Horizonmonths

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$31.03
T+0 close · Feb 25, 2026 · via day close
Latest settled
+19.19%
T+60 · $36.98
Vs SPY
+12.24%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Feb 25 $31.03entry
  2. T+1 · 9mo ago −0.90%α −0.36% · $30.75
  3. T+5 · 9mo ago −6.03%α −4.93% · $29.16
  4. T+20 · 8mo ago −5.41%α −0.18% · $29.35
  5. T+60 · 6mo ago +19.19%α +12.24% · $36.98
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Alkermes reported 2025 total revenues of $1.48 billion and diluted GAAP EPS of $1.43, with a 9% year-over-year increase in proprietary product sales. The company expects a GAAP net loss in 2026 due to acquisition-related costs from the Avadel deal, despite projecting revenue growth to $1.73-$1.84 billion. The acquisition of Avadel strengthens its sleep medicine portfolio with LUMRYZ and supports the development of alixorexton.

Key Financial Metrics

Revenue
$1.5B
-5.3% YoY
EPS
$1.43
Guidance
$1.73B-$1.84B
lowered

Key Facts

  • 2025 total revenue was $1.48 billion, down from $1.56 billion in 2024
  • 2025 GAAP net income was $242 million, down from $367 million in 2024
  • 2026 guidance includes a projected GAAP net loss of $115-$135 million
  • 2026 revenue guidance is $1.73-$1.84 billion, representing 17-24% growth
  • Acquisition of Avadel closed in February 2026 for $775 million in cash and $1.525 billion in term loans
  • LUMRYZ net sales expected to contribute $315-$335 million in 2026

Financial Impact

GAAP net loss of $115-$135 million in 2026 due to $150 million inventory step-up expense and $95-$105 million amortization from Avadel acquisition

revenueepsnet incomeamortizationdebt

Segment Breakdown

SegmentRevenueGrowth
VIVITROL$467.9M+2.3%
ARISTADA$370.0M+6.9%
LYBALVI$346.7M+23.9%

Risk Factors

  • Integration risks from the Avadel acquisition
  • Dilution from $1.525 billion in new debt
  • Execution risk in launching and commercializing LUMRYZ
  • Clinical development risk for alixorexton

Market Snapshot

Exchange
Nasdaq

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-068512
Document: alks-20260225.htm0001193125-26-068512
Document: alks-ex99_2.htm0001193125-26-068512
Document: 0001193125-26-068512-index-headers.html0001193125-26-068512
Document: 0001193125-26-068512-index.html0001193125-26-068512
Document: 0001193125-26-068512.txt0001193125-26-068512

Track record

23 reports on ALKS

Performance horizon

3 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +25.88% at T+60 after the May 12, 2026 report. 3 of 4 went positive at some point.

Filters
  1. Nov 12, 20264d ago 8-K Neutral 4/10 Entry $46.98 Now $46.53 −0.96% settles Feb 10
  2. Nov 4, 202612d ago Institutional Cluster Neutral 3/10 Entry $44.54 Now $46.53 +4.47% settles Feb 3
  3. Nov 3, 202613d ago 144 Neutral 2/10 Entry $45.89 Now $46.53 +1.39% settles Feb 2
  4. Nov 3, 202613d ago 8-K Neutral 5/10 Entry $45.69 Now $46.53 +1.84% settles Feb 1
  5. Sep 21, 20268w ago 8-K Bullish 6/10 Entry $44.00 Now $46.53 +5.76% settles Dec 15
  6. Sep 16, 20268w ago 8-K Neutral 2/10 Entry $46.07 Now $46.53 +1.00% settles Dec 10
  7. Sep 3, 202610w ago Insider Cluster Neutral 2/10 Entry $46.10 Now $46.53 +0.93% settles Dec 1
  8. Aug 3, 202615w ago Insider Cluster Bearish 4/10 Entry $49.67 to $44.32 Now $46.53 +6.32% ▲ +10.77% +11.15% vs SPY
  9. Aug 3, 202615w ago Insider Cluster Neutral 2/10 Entry $49.67 to $44.32 Now $46.53 −6.32% ▼ −10.77% −11.15% vs SPY
  10. Aug 3, 202615w ago Insider Cluster Neutral 3/10 Entry $49.67 to $44.32 Now $46.53 −6.32% ▼ −10.77% −11.15% vs SPY
Showing 10 of 23

US Market Status

Market Closed · Opens Wed (10h 10m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Feb 25, 2026